Lantheus to Complete $8 Billion Nuclear Medicine Acquisition in First Half of 2027
Lantheus has agreed to an $8 billion acquisition that will combine global isotope production, radiodiagnostics and targeted radiotherapy into an integrated nuclear medicine company spanning oncology, neurology and cardiovascular disease across more than 70 countries. Funding combines debt and equity financing with no earnout conditions attached. Closing requires Lantheus shareholder approval plus regulatory and antitrust reviews in multiple markets, with completion expected in the first half of 2027.
Why it matters: The $8 billion deal reshapes the global radiopharmaceutical industry and consolidates the full isotope-to-therapy value chain.